Polus

Polus is a South Korean biopharmaceutical company specializing in the development and manufacturing of biosimilars and protein therapeutics. The company focuses on producing biosimilar versions of biologics including insulin and other therapeutic proteins, using mass culture technology of microorganisms. Founded in March 2016 and headquartered in Incheon, South Korea, Polus was led by CEO Nam Seung-heon, formerly a senior executive at rival Korean biosimilar developer Celltrion. The company's mission centers on medical equality — expanding access to advanced biologic medicines through cost-effective biosimilar manufacturing. Polus develops, produces, and markets biosimilar products targeting both domestic and international pharmaceutical markets.